1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Low levels of WRAP53 predict decreased efficacy of radiotherapy and are prognostic for local recurrence and death from breast cancer : a long-term follow-up of the SweBCG91RT randomized trial
(
- Contribution to journal › Article
-
Mark
Gene expression in metastatic breast cancer—patterns in primary tumors and metastatic tissue with prognostic potential
(
- Contribution to journal › Article
- 2020
-
Mark
Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer : data from a randomised trial with long-term follow-up
(
- Contribution to journal › Article
- 2018
-
Mark
Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial
(
- Contribution to journal › Article
- 2013
-
Mark
St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial
(
- Contribution to journal › Article
- 2012
-
Mark
Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study
(
- Contribution to journal › Article
- 2007
-
Mark
Estrogen receptor beta expression is associated with tamoxifen response in ER alpha-negative breast carcinoma
(
- Contribution to journal › Article
-
Mark
CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma.
(
- Contribution to journal › Article
- 2004
-
Mark
Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival: a validation study
(
- Contribution to journal › Article
- 2003
-
Mark
High preoperative plasma concentration of tissue plasminogen activator (tPA) is an independent marker for shorter overall survival in patients with ovarian cancer.
(
- Contribution to journal › Article